TY - JOUR
T1 - Pain management for medical abortion before 14 weeks’ gestation
T2 - A systematic review
AU - Reynolds-Wright, John J.
AU - Woldetsadik, Mulat A.
AU - Morroni, Chelsea
AU - Cameron, Sharon T.
N1 - Funding Information:
We are grateful to the team at the Cochrane Fertility Regulation Group and the Cochrane Children and Families Network for their support in conducting the review. Funding: This study was conducted in part at the MRC Centre for Reproductive Health, Edinburgh, UK, which is supported by Medical Research Council (UK) grant MR/N022556/1This study was conducted in part at the MRC Centre for Reproductive Health, Edinburgh, UK, which is supported by Medical Research Council (UK) grant MR/N022556/1 Declaration of Competing Interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Funding Information:
This study was conducted in part at the MRC Centre for Reproductive Health, Edinburgh, UK, which is supported by Medical Research Council (UK) grant MR/N022556/1
Publisher Copyright:
© 2022
PY - 2022/12
Y1 - 2022/12
N2 - Introduction: Abortion is common worldwide and increasingly abortions are performed at less than 14 weeks’ gestation using medical methods, specifically using a combination of mifepristone and misoprostol. Medical abortion is known to be a painful process, but the optimal method of pain management is unclear. We sought to identify and compare pain management regimens for medical abortion before 14 weeks’ gestation. Study Design: We conducted our search in August 2019 and included randomized controlled trials (RCT) and observational studies of any pain relief intervention (pharmacological and non-pharmacological) for mifepristone-misoprostol combination medical abortion of pregnancies less than 14 weeks’ gestation. Results: We included four RCTs and one observational study. Due to the heterogeneity of study designs, interventions and outcome reporting, meta-analysis was not possible. Only one study found evidence of an effect between interventions on pain score: a prophylactic dose of ibuprofen 1600mg likely reduces the pain score when compared to a dose of paracetamol 2000mg (MD 2.26/10 [CI 3-1.52 lower]). For other interventions (pregabalin 300mg vs placebo; ibuprofen 800mg vs placebo; therapeutic vs prophylactic administration of ibuprofen 800mg; ambulation vs non-ambulation during treatment) there appeared to be little to no difference with comparator. Conclusions: The findings of this review provide some support for the use of ibuprofen as a single dose given with misoprostol prophylactically, or in response to pain as needed. The optimal dosing of ibuprofen is unclear, but a single dose of ibuprofen 1600mg was shown to be effective and it was less certain whether 800mg was effective.
AB - Introduction: Abortion is common worldwide and increasingly abortions are performed at less than 14 weeks’ gestation using medical methods, specifically using a combination of mifepristone and misoprostol. Medical abortion is known to be a painful process, but the optimal method of pain management is unclear. We sought to identify and compare pain management regimens for medical abortion before 14 weeks’ gestation. Study Design: We conducted our search in August 2019 and included randomized controlled trials (RCT) and observational studies of any pain relief intervention (pharmacological and non-pharmacological) for mifepristone-misoprostol combination medical abortion of pregnancies less than 14 weeks’ gestation. Results: We included four RCTs and one observational study. Due to the heterogeneity of study designs, interventions and outcome reporting, meta-analysis was not possible. Only one study found evidence of an effect between interventions on pain score: a prophylactic dose of ibuprofen 1600mg likely reduces the pain score when compared to a dose of paracetamol 2000mg (MD 2.26/10 [CI 3-1.52 lower]). For other interventions (pregabalin 300mg vs placebo; ibuprofen 800mg vs placebo; therapeutic vs prophylactic administration of ibuprofen 800mg; ambulation vs non-ambulation during treatment) there appeared to be little to no difference with comparator. Conclusions: The findings of this review provide some support for the use of ibuprofen as a single dose given with misoprostol prophylactically, or in response to pain as needed. The optimal dosing of ibuprofen is unclear, but a single dose of ibuprofen 1600mg was shown to be effective and it was less certain whether 800mg was effective.
UR - http://www.scopus.com/inward/record.url?scp=85138827304&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2022.08.005
DO - 10.1016/j.contraception.2022.08.005
M3 - Review article
C2 - 36055363
AN - SCOPUS:85138827304
SN - 0010-7824
VL - 116
SP - 4
EP - 13
JO - Contraception
JF - Contraception
ER -